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Abstract
Background: Women with breast cancer, particularly individuals diagnosed at a relatively early age, have an
increased incidence of fractures. Fractures can have serious clinical consequences including the need for major
surgery, increased morbidity and mortality, increased cost of disease management, and reduced quality of life for
patients. The primary cause of the increased fracture risk appears to be an accelerated decrease in bone mineral
density (BMD) resulting from the loss of estrogenic signaling that occurs with most treatments for breast cancer,
including aromatase inhibitors. However, factors other than BMD levels alone may influence treatment decisions to
reduce fracture risk in this setting. Our purpose is to review current evidence for BMD loss and fracture risk during
treatment for breast cancer and discuss pharmacologic means to reduce this risk.
Results: Fracture risk during treatment for breast cancer may be influenced by the rate of BMD loss and the
consequent rapid alterations in bone microarchitecture, in addition to the established fracture risk factors in
postmenopausal osteoporosis. The rapid decrease in BMD during adjuvant chemoendocrine therapy for breast
cancer may necessitate more aggressive pharmacotherapy than is indicated for healthy postmenopausal women
who develop osteoporosis. Over the last few years, clinical trials have established the effectiveness of
bisphosphonates and other antiresorptive agents to preserve BMD during adjuvant therapy for early breast cancer.
In addition, some bisphosphonates (eg, zoledronic acid) may also delay disease recurrence in women with
hormone-responsive tumors, thereby providing an adjuvant benefit in addition to preserving BMD and potentially
preventing fractures.
Conclusions: It is likely that a combined fracture risk assessment (eg, as in the WHO FRAX algorithm) will more
accurately identify both women with postmenopausal osteoporosis and women with breast cancer who require
bone-protective therapy.
Keywords: adjuvant therapy, aromatase inhibitor, bisphosphonate, chemotherapy-induced menopause, osteoporo-
sis, zoledronic acid
Review
Incidence of Fractures in Women With Breast Cancer
Women with breast cancer (BC), even in the absence of
skeletal metastases, are known to have a higher inci-
dence of fractures than women of the same age without
BC. A case control study performed before aromatase
inhibitors (AIs) were part of standard medical practice
showed that at the time of diagnosis, women with BC
did not have a higher prevalence of vertebral fracture
than controls. However, when followed after diagnosis,
women with nonmetastatic BC had a higher rate of
fractures compared with age- and weight-matched con-
trols [1]. Fracture incidence was even higher (HR =
22.7; 95% CI = 9.1, 57.1; P < .0001) in women with
recurrent disease but without skeletal metastases (Table
1) [1]. The increase in fracture incidence was main-
tained in analyses excluding women who eventually
developed skeletal metastases (HR = 2.8; 95% CI = 1.3,
6.2). These data are rendered even more compelling by
the investigators’ caveat that the risk of vertebral frac-
tures may have been underestimated because approxi-
mately 50% of the patients were taking clodronate,
which has been shown to decrease rates of bone mineral
density (BMD) loss and fracture [2,3]. Although it is
now evident that an individual’s risk of fracture can be
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BMD levels and rates of BMD decrease remain key fac-
tors influencing bone health and fracture risk.
In a prospective analysis of postmenopausal women
from the Women’s Health Initiative Observational Study
(WHI-OS),[4] fracture rates for BC survivors, standar-
dized by age, weight, ethnicity, and geographic area,
were increased by 68.6 fractures per 10,000 person-years
compared with women without BC (Figure 1) [4]. The
increased risk of fracture was significant for women
with a BC diagnosis regardless of age (HR ~1.3; P < .001
in the < 55 years and the ≥ 55 years groups), and was
not limited to asymptomatic vertebral fractures.
The increased risk of fracture in BC patients has
become even more evident following the increased use
of AIs as adjuvant therapy. Despite substantial improve-
ments in disease-free survival compared with tamoxifen,
both steroidal (eg, exemestane) and non-steroidal (eg,
anastrozole and letrozole) AIs have been associated with
rapid loss of BMD and increased fracture risk in clinical
trials [5-7]. Although this increase in fracture risk
appears to be reversible on discontinuation of AI treat-
ment,[5,6] it has now become evident that the rate of
BMD loss during AI therapy far exceeds the BMD loss
observed in postmenopausal osteoporosis (PMO),[8] and
is therefore likely to need proactive management to pre-
serve BMD and prevent fractures.
Clinical Implications of Fractures
The incidence of fractures increases with age because of
age-related osteoporosis and decreasing estrogen levels
(Figure 2) [9]. In addition, cancer therapy-induced bone
loss (CTIBL) early in the course of BC, and bone metas-
tases (malignant bone disease) in advanced disease, both
contribute to increased fracture risk. Fractures and
other skeletal complications can have serious clinical
consequences.
Osteoporosis is characterized by decreased bone
strength and increased fracture risk (including hip and
Table 1 Vertebral fracture incidence in women with breast cancer
Controls
a (n = 776) Breast cancer, at diagnosis (n = 352) Breast cancer, recurrent
c (n = 82)
Follow-up, years ± SD 2.9 ± 0.3 2.1 ± 1.2 1.8 ± 1.4
Prevalence of vertebral fractures, % 5.2 6.0 30.5
Annual fracture incidence, % 0.53 2.72 19.21
Mean number of fractures
b 1.08 1.45 1.69
Mean severity score
b 2.00 2.45 4.10
Abbreviation: SD, standard deviation.
a 25% were current or past users of hormone-replacement therapy.
b In patients with a fracture.
c Excluding bone.
Adapted by permission from Macmillan Publishers Ltd: Br J Cancer,[1] copyright 1999.
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Figure 1 Age-standardized fracture incidence rates.
Standardized rates were calculated using the age distribution of the
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years are above each set of bars. Reprinted with permission from
Chen Z, et al. Arch Intern Med. 2005;165:552-558 [4]. Copyright
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Page 2 of 9vertebral fractures), and is a significant health concern
in the developed world. Hip fractures secondary to
osteoporosis are associated with an approximately 2-fold
increase in mortality during the 12 months following
the fracture [10]. Hip fractures result in prolonged hos-
p i t a l i z a t i o n( a na v e r a g eo f1 6 . 3d a y si na no r t h o p e d i c
ward and 63.6 days in a rehabilitation hospital in 1
study) and are associated with increased risks of deep
vein thrombosis (DVT; reported in up to 31% of
patients undergoing surgery for hip fractures), pulmon-
ary emboli, and pressure ulcers [11-14]. Moreover,
approximately 20% of patients discharged after success-
ful surgery for hip fractures are referred back for in-
patient hospital care with suspected DVT or pulmonary
embolism within 3 months [12]. Vertebral fractures can
be associated with chronic pain and decreased pulmon-
ary function [15].
Because CTIBL can occur much more rapidly than
age-related PMO (Figure 3[16]), adjuvant treatment for
BC substantially increases the risk of fractures, especially
in postmenopausal women [17,18]. Fractures, whether
attributable to PMO or to CTIBL, can significantly
decrease mobility, functional autonomy, and quality of
life [19]; and greatly increase disease-management costs
[10]. Moreover, fractures are also associated with
reduced survival (especially in the first 6 months post-
fracture) [10]. Recent data indicate that all types of
osteoporotic fractures increase the risk of death by 42%
to 2.4-fold for at least 5 years after fracture incidents,
and mortality risk remains elevated for up to 10 years
after a hip fracture [20]. This article investigates the cri-
tical need for precise assessment of fracture risk to opti-
mally manage patients with early BC.
Risk Factors for Fracture
Numerous risk factors for the development of bone loss
and fractures have been identified (Table 2) [4,21].
These are categorized as modifiable or other risk factors
[4,21,22]. Some risk factors such as age are generally
applicable to all women, whereas other risk factors are
specific to women with BC who are receiving therapeu-
tic interventions, including radiation therapy, che-
motherapy, AIs, and steroids. For example, in women
with early stage BC who were treated with conservative
surgery and radiation therapy (N = 1,624), there was a
dose-dependent relationship between radiation and rib
fracture incidence [23]. Chemotherapy is also associated
with increased fracture risk in premenopausal women
with BC because it can induce early menopause and
may have direct, toxic effects on bone cells. In a case-
control study (N = 44 pairs), premenopausal patients
with BC receiving chemotherapy had significantly lower
lumbar spine BMD compared with age-matched patients
not receiving chemotherapy (1.17 versus 1.29 g/cm
2), a
difference that was attributed to the high incidence of
iatrogenic menopause in the chemotherapy group [24].
It has been estimated that premature menopause preci-
pitated by adjuvant chemotherapy may hasten fractures
by approximately 10 years in a large proportion of pre-
menopausal women with BC whose disease is in remis-
sion [24]. Indeed, CTIBL in patients with
chemotherapy-induced premature menopause leads to a
marked decrease in BMD within a short period of time
(Figure 3) [16]. In addition to chemotherapy-induced
menopause, reversible ovarian suppression (eg, using
goserelin) has also been associated with similarly rapid
rates of BMD loss (up to 7.7% within the first year) [25].
Ovarian failure secondary to chemotherapy
AI therapy plus gonadotropin-releasing hormone agonist
Androgen deprivation therapy
Bone marrow transplant
Aromatase inhibitor (AI) therapy
Early menopausal women
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levels in postmenopausal women who have hormone
receptor-positive BC, are also associated with rapid
BMD loss and increased fracture risk. In long-term fol-
low-up of phase III trials of AIs versus tamoxifen as
adjuvant therapy for early stage BC, the incidence of
fractures was reported to be 33% to 43% higher in AI-
treated patients compared with tamoxifen [5-7]. This
increase in fracture risk is maintained at least for the
duration of AI therapy. The risk appears to wane after
completion of treatment,[5,6] but more robust off-
treatment data are needed to confirm this observation.
Overall, because AIs are now replacing tamoxifen as
the treatment of choice for postmenopausal women
with early stage BC, steps should be taken to identify
patients at risk for fractures to ensure proper prophy-
lactic treatment.
Steroids (which BC patients may have received pre-
viously or concurrently for pre-existing conditions,
underlying symptoms, or control of emesis) can also
increase fracture risk [26]. In addition, postmenopausal
women with BC may have fracture risk factors that are
independent of their BC therapy, but nonetheless
increase their fracture risk. Bone mineral density is an
established key determinant of fracture risk and has
been incorporated into many clinical guidelines for
assessing fracture risk [27-29]. Osteoporosis is still
defined on the basis of BMD measurement. Thus, the
World Health Organization (WHO) defines osteopenia
(BMD T-score < -1.0 and > -2.5) and osteoporosis
(BMD T-score ≤ -2.5) relative to peak bone mass for
premenopausal women and advocates bone-directed
therapy for all women with osteoporosis. However,
many risk factors that are independent of BMD (Table 2
[4,21]) also significantly increase fracture risk, including
increasing age, low body mass index, personal or family
history of fractures, and current or history of smoking
[22,30].
Mechanisms of Accelerated Bone Loss in Breast Cancer
Differ From Postmenopausal Osteoporosis
The risk of fragility fractures increases progressively and
continuously as BMD decreases [31]. Several mechan-
isms contribute to bone loss in BC patients. Breast can-
cer itself, in the absence of bone metastases, might
interfere directly with bone metabolism, for example
increasing osteoclastic activity by stimulating the release
of transforming growth factors [4]. Bone loss can also
arise because of low estrogen levels caused by che-
motherapy-induced ovarian failure or ovarian function
suppression in premenopausal women [25,32]. In addi-
tion, AI therapy to suppress peripheral estrogen produc-
tion in postmenopausal women can exacerbate age- and
menopause-related BMD loss [5-7,17,33]. In general,
decreased estrogen levels are associated with increased
fracture risk (Figure 2) regardless of the mechanism
underlying such hypogonadism [9].
Bone loss associated with BC treatment is substan-
tially more rapid than during natural menopause.
Women undergo an accelerated, transient phase of
bone loss during natural menopause (~3% per year
during the first 1-2 years, slowing to approximately 1%
annually thereafter) [34]. In contrast, surgically
induced menopause (oophorectomy) causes a larger
reduction of total bone mass of up to 20% within 18
months in some studies, and BMD appears to continue
decreasing thereafter [35]. Similarly, ovarian suppres-
sion with goserelin in premenopausal women can
decrease BMD by 6% to 10% within the first 2 years
[36]. The effect of goserelin-induced ovarian suppres-
sion in combination with AIs in this population is
even more severe, with reports of up to 17.3% BMD
loss within 3 years compared with baseline (P < .0001)
in 1 study [25]. The rate of bone loss is also marked in
postmenopausal women undergoing treatment with
AIs, which block conversion of androgens to estrone
and estradiol, thereby effectively eliminating estrogenic
Table 2 Risk factors for development of fractures or bone mineral density loss
a
Modifiable risk factors Other risk factors
Excessive alcohol consumption
Tobacco use
Existing low body mass index (< 20 kg/m
2) and excessive weight loss
Falls
Sedentary lifestyle
b
Low calcium or vitamin D intake
Use of medications affecting absorption of calcium
or absorption or production of vitamin D
b
Use of corticosteroids
b
Use of medications decreasing the production of estrogen or testosterone
b
Low estrogen or testosterone levels
Age
Low bone mass
Race (Asian, white)
Fracture history (personal, familial)
b
Diabetes
Rheumatoid arthritis
Emphysema, chronic bronchitis
Renal insufficiency
a Adapted with permission of the Oncology Nursing Society from Maxwell C, Viale PH. (2005) Cancer treatment-induced bone loss in patients with breast or
prostate cancer. Oncol Nurs Forum. 2005;32:589-603 [21].
b Data from Chen Z, et al. Arch Intern ed. 2005;165:552-558 [4].
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continues throughout the duration of therapy, and
averages approximately 2% per year [8,38]. The nega-
tive effect of estrogen depletion on bone appears to be
associated with all AIs [17,33]. This class effect high-
lights the necessity to monitor bone loss and fracture
risk in all patients receiving AI therapy, and suggests
that pharmacotherapy may be needed in some patients
to prevent bone loss and reduce fracture risk.
Several clinical trials have investigated bisphospho-
nates and other antiresorptive agents for the preven-
tion of AIBL in nonosteoporotic patients. These
include studies of oral ibandronate (Arimidex
® Bon-
dronat
®;A R I B O N ) , [ 3 9 ]r i s e d r o n a t e( S t u d yo fA n a s t r o -
zole with the Bisphosphonate RisedronatE; SABRE),
[40] denosumab (Hormone Ablation Therapy in Breast
Cancer; HALT-BC),[41] and 4 independent trials of
intravenous zoledronic acid: 1 in premenopausal
(ABCSG-12)[25] and 3 in postmenopausal women
(Zometa/Femara Adjuvant Synergy Trials; Z-FAST,
ZO-FAST, E-ZO-FAST) [42-44]. Results from these
trials demonstrate that upfront bone-directed therapy
effectively prevents bone loss and maintains or
increases BMD in women receiving AIs or other endo-
crine therapy for early BC. In addition, it has been
shown that the addition of zoledronic acid to adjuvant
endocrine therapy may also improve clinical outcomes
(ie, delay disease recurrence in bone and other sites)
compared with endocrine therapy alone in pre- and
postmenopausal women with early stage hormone-
responsive BC [44-46].
Monitoring Fracture Risk
Although BMD is a good surrogate for bone strength, a
substantial proportion of women with fractures do not
have osteoporosis (defined as T-score < -2.5; Figure 4)
[47]. This may be related to the fact that BMD does not
capture many factors that influence bone strength, such
as bone size, bone geometry, and microarchitecture
change [48]. Currently, overall risk assessment, including
but not limited to BMD measurements, is recommended
by the WHO[29] and the National Osteoporosis Foun-
dation (NOF),[27] which suggest using the FRAX[49]
tool to compute fracture risk. The FRAX algorithm uses
the femoral neck BMD T-score (if available), age, body
mass index, personal and family history of fractures,
corticosteroid treatment, lifestyle factors (smoking and
alcohol consumption), and comorbidities (rheumatoid
arthritis; secondary osteoporosis) to compute the 10-
year risk of hip and other osteoporotic fractures [49].
The FRAX tool represents an important advance in
understanding and accounting for the multifactorial nat-
ure of fracture risk and has been customized for various
countries and ethnicities where epidemiologic data are
available. The greatest benefit of the FRAX tool is the
consideration of clinical risk factors for fracture, and not
only BMD, in the decision to prescribe an antiosteo-
porotic treatment.
Estimation of fracture risk in women with breast can-
cer has a further level of complexity in that the disease
and its treatment can, in themselves, alter BMD (and.
therefore, fracture risk). The FRAX tool has some inher-
ent limitations when applied to patients with breast
Fracture rate
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Page 5 of 9cancer–because this tool has been validated using popu-
lation-based studies in generally healthy postmenopausal
women, it might not take factors specific to breast can-
cer (eg, the rate of bone loss, the effect of anticancer
therapies that cause hypogonadism) into sufficient
account [50]. Furthermore, FRAX does not adjust for a
“dose-response” in fracture risk factors; this might be
especially relevant in the breast cancer setting, wherein
long-term treatment with AIs as well as other causes of
bone loss would be included under the single “secondary
osteoporosis” feature in the FRAX tool, thereby resulting
in underestimation of the neti n c r e a s ei nf r a c t u r er i s k .
The duration of AI therapy is also not taken into
account. Nonetheless, the FRAX index assesses fracture
risk using a comprehensive list of clinical and individual
risk factors, and can be used to compute long-term frac-
ture risk even in the absence of BMD measurements
[49]. Although some guidelines (eg, American Society of
Clinical Oncology [ASCO] guidelines) continue to
recommend thresholds for bone-directed therapy based
primarily on BMD, the last 2 to 3 years have witnessed
a growing awareness of fracture risk factors beyond
BMD T-scores.
Recent clinical guidelines have already begun to
include fracture risk factors for patient assessment and
treatment decisions,[22,30,51] and have even attempted
to refine the FRAX approach specifically for the breast
cancer setting by using a similar combination of fracture
risk factors, but with more well-defined criteria (instead
of yes/no) in an attempt to address the unique bone
health challenges posed by adjuvant endocrine therapy.
In a recent consensus statement from an international
panel of bone health experts, periodic monitoring of
BMD levels is recommended for all women with breast
cancer receiving AI therapy, and pharmacologic inter-
vention is suggested for patients with normal T-scores
or mild osteopenia if they experience an annual BMD
decrease of 10% or more compared with pretreatment
levels [52]. Moreover, this treatment algorithm recom-
mends bone-directed therapy regardless of baseline
BMD for women with multiple fracture risk factors (≥ 2
predefined fracture risk factors similar to those
described in Table 2) [52]. The most comprehensive
fracture risk assessment algorithm for patients with
early breast cancer is described in a position statement
from an expert panel in the United Kingdom [51]. This
algorithm classifies patients into low-, intermediate-,
and high-risk groups for fracture based on hormonal
status (eg, premature menopause/use of AIs), fracture
history, secondary osteoporosis, and BMD changes dur-
ing adjuvant therapy for breast cancer [51]. Such algo-
rithms for fracture risk assessment specifically in the
breast cancer setting should help guide treatment deci-
sions to preserve bone health in such patients.
Conclusions
It is now clear that women with BC have an increased
fracture risk compared with age-matched women with-
out BC. In addition to established risk factors such as
BMD, women with BC may be exposed to numerous
factors that reduce bone strength and structural integ-
rity. The most notable fracture risk factors include
advancing age (> 65 years), AI therapy, chemotherapy-
induced menopause, tamoxifen use in premenopausal
women, low body-mass index (< 20 kg/m
2), a family his-
tory of hip fracture, a personal history of fragility frac-
ture after age 50, corticosteroid use, excessive alcohol
consumption, and smoking [22,30]. The combination of
these genetic, environmental, and cancer treatment-
related factors contributes to the increased fracture risk
observed in women with BC, especially women receiving
AI therapy (Figure 5). Furthermore, a recent analysis
suggests that combining clinical fracture risk factors
with BMD may offer the most accurate overall assess-
ment of fracture risk [53].
It is likely that a combined fracture risk assessment
will more accurately identify both women with PMO
and women with BC who require bone-protective ther-
apy; moreover, treatment options (ie, drug choice, dose,
and frequency) should probably be influenced by the
severity of the BMD loss. For example, the most com-
mon therapies used to effectively treat the slow BMD
loss observed in women with PMO (eg, oral bispho-
sphonates, calcium and vitamin D supplements) may
not be optimal for prevention of accelerated BMD loss
secondary to chemotherapy-induced menopause, the use
of gonadotropin-releasing hormone (GnRH) analogues
in premenopausal women, or AI therapy in postmeno-
pausal women.
Monitoring and treatment recommendations to reduce
fracture risk in women with early breast cancer
Bone health assessment in women undergoing adjuvant
therapy for breast cancer should include BMD T-score
measurement at baseline and at least every 1 to 2 years
during treatment, together with assessment of estab-
lished risk factors for fracture, as defined by an interna-
tional expert panel [52]. Women with moderate to
severe osteopenia or additional fracture risk factors
should receive bone-targeted treatment. Treatment
should be continued for the duration of endocrine ther-
apy. Currently there are no approved therapies specifi-
cally for preventing BMD loss in women receiving
treatment for BC, although several recent clinical trials
have sought to address this issue. The most robust data
currently available in terms of the numbers of patients
treated and duration of follow-up (for safety and effi-
cacy) support the use of zoledronic acid (4 mg twice a
year) to prevent CTIBL/AIBL in women receiving
Body BMC Cancer 2011, 11:384
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Page 6 of 9adjuvant endocrine therapy [42-44]. Smaller trials also
support the activity of oral bisphosphonates and the
new antiresorptive agent denosumab in this setting
[39-41]. Although none of these trials specifically
addressed the influence of clinical risk factors on frac-
ture risk in this patient population, it is logical to infer
that bone-directed therapy will be essential in women
receiving AIs who also have multiple fracture risk fac-
tors. In addition, the delay in disease recurrence
observed in the trials of zoledronic acid supports the
potential for anticancer benefits from a therapy designed
to preserve bone integrity [44-46]. Ongoing trials are
evaluating whether other bisphosphonates and denosu-
mab might also provide similar benefits,[54] and the
results are eagerly awaited.
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